Endeavor BioMedicines

top of page

May 20, 2024

ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF

John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...

John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF

Apr 26, 2024

Company News

John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF

He describes the phase 2 data in IPF that Endeavor unveiled in January and enabled this week's raise.

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

At Savills, the Life Sciences Team specializes in helping biotech companies unlock their full potential by aligning real estate strategies with their scientific and business goals. As a leading global commercial real estate advisory firm, we focus exclusively on occupier services and tenant representation, acting as a trusted partner to some of the most innovative companies in the industry.

Visit Savills' Life Sciences Overview

bottom of page

ATS2024: Endeavor BioMedicines' Hedgehog inhibitor showed improvements in lung function, capacity, and other measures at 12-weeks in IPF

John Hood on Endeavor's $132.5M series C and hedgehog inhibition for IPF

Follow BiotechTV

Sponsors

Sponsor Spotlight